Kinarus Therapeutics Holding AG

Business Combination of Kinarus Therapeutics Holding AG (now renamed to Curatis Holding AG) and Curatis AG completed

Kinarus Therapeutics Holding AG publishes FY2023 Financial Statements and announces details on Business Combination with Curatis AG and Reverse Share Split

Extraordinary General Meeting of Kinarus Holding approved all resolutions relating to the envisaged Business Combination with Curatis

Publication of unaudited financial statements of Kinarus Therapeutics Holding AG (only) for FY2023

Courts of Basel-Stadt have revoked bankruptcy of Kinarus Therapeutics Holding AG

Kinarus Therapeutics Holding AG in Liquidation and Curatis AG propose to combine companies and reverse bankruptcy procedures of Kinarus Therapeutics Holding AG in Liquidation

Kinarus Therapeutics has decided to file for bankruptcy

Kinarus Therapeutics Group Reports First Half 2023 Financial Results

Kinarus Therapeutics signed licensing agreement to extend cash for operations

Kinarus Therapeutics Announces Personnel Changes

Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting

Kinarus Therapeutics signed subordinated bridge loans to ensure further liquidity

Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting

Kinarus Therapeutics Group Reports 2022 Annual Results

Kinarus Therapeutics signed CHF1.5 million convertible loan agreement with ChaoDian (Hangzhou) Investment Management

Kinarus Therapeutics Reports Key Unaudited Full Year 2022 Figures

Kinarus Therapeutics Holding AG (‘Kinarus’) receives deadline extension from SER for publication of its 2022 annual financial report

Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update

Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan

Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5

Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001

Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China

Kinarus Therapeutics Provides Strategic Update

Kinarus Therapeutics Provides Strategic Update

Kinarus Therapeutics Announces Discontinuation of the Phase 2 KINETIC Study of KIN001 in Hospitalized COVID-19 Patients Following a Prespecified Interim Analysis of Efficacy and Safety

Kinarus Therapeutics Reports H1 2022 Financial Results and Provides Corporate Update

Kinarus Therapeutics initiates KIN001 Phase II KINFAST clinical trial in COVID-19 outpatients

Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19

Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville

Kinarus Therapeutics to host KOL event on Monday, June 27, to discuss therapies in wet Age-Related Macular Degeneration and potential advantages of KIN001